ABSTRACT
BACKGROUND: Atopic dermatitis (AD) is a common, chronic type 2 inflammatory skin disease, typically starting in infancy, with increased risk for subsequent extracutaneous atopic morbidities. Dupilumab is the first biologic agent targeting type 2 inflammation approved by the U.S. Food and Drug Administration (USFDA); it was licensed in 2017 for adults with moderate to severe AD and 2 years later for adolescents. Systemic treatment for pediatric AD remains a significant unmet medical need. OBJECTIVE: To analyze off-label use of dupilumab in children with AD. METHODS: Multicenter retrospective review that evaluated children who were prescribed dupilumab for moderate to severe AD. RESULTS: One hundred eleven of 124 patients (89.5%) gained access to dupilumab after a mean of 9 weeks. The dosing range was 4 to 15.5 mg/kg for the loading dose and 2.0 to 15.3 mg/kg every other week for maintenance. The range was widest for 6- to 11-year-olds and was related to use of either full or half of adult dosing. Associated morbidities, treatment response, and adverse events were comparable to those in previous adolescent and adult trials. LIMITATIONS: The retrospective design of the study limited uniform data collection. CONCLUSION: Access to dupilumab was achievable for the majority of children after a mean 9-week delay because of insurance payment denial. This review supports dupilumab response and tolerability in children. Optimal dosing for patients younger than 12 years has not been defined. Availability of the drug in 2 different concentrations is an important safety issue.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Dermatitis, Atopic/drug therapy , Off-Label Use/statistics & numerical data , Child , Child, Preschool , Female , Humans , Infant , Male , Retrospective Studies , Severity of Illness IndexABSTRACT
Acquired perforating dermatosis (APD) is characterized by pruritic craterlike lesions with a predilection for patients affected by chronic kidney disease or diabetes mellitus (DM). We present a case of a 57-year-old black woman admitted for chest pain and dyspnea who was found to have 2 teardrop-shaped yellow-white-chalky plaques consistent with APD that developed at the site of a preexisting split-thickness skin graft (STSG). We also review the literature on APD.
Subject(s)
Diabetes Mellitus, Type 2 , Heart Failure , Kidney Failure, Chronic , Skin Diseases/diagnosis , Skin Transplantation , Chest Pain/etiology , Diagnosis, Differential , Dyspnea/etiology , Female , Forearm , Humans , Middle Aged , Skin Diseases/pathologyABSTRACT
Otophyma is a rare condition characterized by edematous deformation of the ear that is considered to be the end-stage of an inflammatory process such as rosacea and eczema. This report illustrates a case in an elderly male, originally thought to have leprosy. Biopsy revealed a nodular infiltration of inflammatory cells around adnexal structures and an intraepidermal cyst. No acid-fast organisms were identified. We present a patient who is of a different ethnic group than usually seen with this disease and provide a review of the clinical presentation, histopathological features, and management of this rare condition.
